###### Key questions

What is already known about this subject?
=========================================

-   Transcatheter aortic valve implantation (TAVI) is cost-effective compared with surgical aortic valve replacement (SAVR) for severe aortic stenosis; however, it is on average a more expensive procedure.

What does this study add?
=========================

-   We have identified potentially modifiable factors that drive in-hospital costs for TAVI and SAVR. These include prolonged intensive care unit stay and the use of non-femoral access, for example.

How might this impact on clinical practice?
===========================================

-   We have identified potential areas for quality improvement efforts to reduce overall costs, and to improve the efficiency of care delivery for patients with severe aortic stenosis.

Introduction {#s1}
============

Valvular heart disease is considered the next cardiovascular epidemic in developed countries, with a prevalence that rises exponentially with the ageing demographic.[@R1] Severe aortic stenosis (AS) is the most common form of valvular disease that requires intervention,[@R2] traditionally with surgical aortic valve replacement (SAVR). Transcatheter aortic valve implantation (TAVI) has rapidly evolved to become the treatment of choice for patients with severe AS, who are either inoperable or at high surgical risk.[@R3] Landmark multicentre randomised controlled trials of TAVI[@R4] have shown comparable or superior outcomes compared with SAVR, which has led to the widespread dissemination of this technology.[@R11] Ongoing trials are evaluating the efficacy of TAVI compared with SAVR in low-risk and intermediate-risk AS patient populations.[@R12]

As the indications for TAVI expand to lower risk cohorts[@R12] with a corresponding shift in referral patterns from SAVR to TAVI, it is important to understand the relative resource intensity of each procedure. There have been multiple cost-effectiveness analyses that have compared TAVI to SAVR in high-risk cohorts; the majority of these suggest that TAVI is an economic attractive intervention that represents good value.[@R13] Investigators have evaluated the impact of complications on the hospitalisation costs associated with TAVI, and have found that complications contribute up to 25% of episode costs.[@R17] However, there is a paucity of data on other patient-level and procedural-level drivers of healthcare cost associated with the episode of care for each of these procedures and specifically comparing the drivers for SAVR versus TAVI. Such data are important in order to identify potential modifiable factors, such that the efficiency of healthcare delivery can be improved. In the current economic climate of highly constrained healthcare budgets, it is imperative that the allocation of scarce healthcare resources be optimised.

Accordingly, the objective of our study was to address this gap in knowledge by evaluating healthcare costs associated with the episode of care for patients with severe AS undergoing either SAVR or TAVI in Ontario, Canada, and identifying the drivers of resource usage.

Methods {#s2}
=======

This retrospective cohort study was conducted in the province of Ontario in Canada. Ontario has a population of ∼13.6 million, all of whom received publicly funded universal medical coverage, provided by a single third party payer, the Ontario Ministry of Health and Long Term Care (MOHLTC).

Data sources {#s2a}
------------

All patients who underwent a SAVR or TAVI procedure from 1 April 2012 to 31 March 2013 were identified through the Cardiac Registry at the Cardiac Care Network (CCN) of Ontario. CCN includes a network of the 19 hospitals that offer invasive cardiac procedures including coronary artery bypass grafting (CABG), TAVI and SAVR.[@R21] [@R22] CCN maintains a registry of all patients who have undergone these procedures, and contains data on patient demographics, comorbidities as well as procedural details including coronary anatomy. Data entry into the CCN Cardiac Registry is a mandatory pre-requisite for provincial funding. The validity of the CCN Cardiac Registry has been evaluated through selected chart audits and core laboratory verification.[@R23] CCN is a prescribed entity under provincial privacy legislation, which permits CCN to collect and use personal patient information without the need for patient consent.

The Ontario Case Costing Initiative (OCCI) is a single source for integrated financial and clinical information that is available via the MOHLTC. Comprehensive primary costing data collection is performed by the accounting/costing centres at hospitals and includes both direct (eg, variable and fixed labour and both general and service-recipient specific supplies) and indirect costs. These are then merged with clinical information, including most responsible diagnosis, case-mix groupers, procedural information and length of hospital stay. During the time period of interest, 7 of the 11 cardiac surgery hospitals (of which 10 performed TAVI and all 11 performed SAVR) in the province were contributing data to OCCI. The cases captured in OCCI represented \>50% of TAVI and SAVR volumes in the province.

Patients {#s2b}
--------

We included all patients who underwent TAVI, isolated SAVR and combination SAVR+CABG at the six OCCI participating hospitals from 1 April 2012 to 31 March 2013.

Healthcare costs {#s2c}
----------------

Our primary outcome was individual-level cumulative healthcare costs for the index hospitalisation, defined as the acute hospitalisation during which the valve procedure was performed. All costs were reported in 2013 Canadian dollars.

Statistical analysis {#s2d}
--------------------

Healthcare costs have a number of statistical properties that preclude the use of traditional statistical tools, including a heavily right-skewed distribution.[@R24] We used hierarchical generalised linear models with a logarithmic link and γ distribution to account for these features of costing data.[@R24] The models were clustered by hospital. The logarithmic link function restricts predicted costs to positive values, and produces final model coefficients that are straightforward to interpret.[@R27] Specifically, the exponential of the coefficient provides a rate ratio (RR) interpreted as the percentage increase in the mean cost for each unit change in the predictor.

SAS V.9.3 (SAS Institute, Cary, North Carolina, USA) was used for all analyses; p values of \<0.05 were considered significant.

Results {#s3}
=======

Cohort {#s3a}
------

The cohort consisted of 1310 patients, of whom 585 underwent SAVR, 518 had combination SAVR+CABG, while 207 had TAVI. As seen in [table 1](#OPENHRT2016000468TB1){ref-type="table"}, the groups had marked differences in their baseline characteristics, with older and higher risk patients undergoing TAVI. The mean age of patients undergoing isolated SAVR was 67.5 years, with the majority under the age of 75 years. In contrast, the mean age of the patients undergoing TAVI was 81.7 years, and they had a substantially higher comorbidity burden, including prevalence of lung disease, peripheral vascular disease and renal dysfunction, consistent with these being high-risk or inoperable patients.

###### 

Baseline characteristics

                               Total (n=1310)   Isolated SAVR (n=585)   SAVR with CABG (n=518)   TAVI (n=207)   p Value
  ---------------------------- ---------------- ----------------------- ------------------------ -------------- ----------
  *Patient-level factors*                                                                                       
  Demographics                                                                                                  
   Age                                                                                                          
    20--74                     49.4             66.5                    43.8                     15.0           \<0.0001
    75+                        50.6             33.5                    56.2                     85.0           \<0.0001
    Mean±SD (years)            72.4±11.3        67.5±12.2               74.3±8.4                 81.7±7.2       
    Female                     36.3             39.5                    29.2                     44.9           \<0.0001
  Medical comorbidities                                                                                         
   COPD                        9.4              6.3                     9.7                      17.4           \<0.0001
   CVD                         11.4             7.4                     12.2                     20.8           \<0.0001
   PVD                         12.8             5.6                     16.2                     24.6           \<0.0001
   BMI**\***                                                                                                    0.0002
    Underweight/normal         21.1             20.2                    20.1                     26.1           
   Overweight                  71.3             70.8                    75.7                     61.8           
   Missing                     7.6              9.1                     4.2                      12.1           
   Renal function                                                                                               \<0.0001
   Creatinine 0--140 μmol/L    82.8             84.1                    86.5                     70.0           
   Creatinine \>140 μmol/L     10.3             7.9                     10.0                     17.9           
   Missing                     6.9              8.0                     3.5                      12.1           
   Dialysis                    2.0              1.2                     3.1                      1.4            0.0666
   Anticoagulant use           13.4             10.8                    11.2                     26.6           \<0.0001
  Cardiac risk factors                                                                                          
   Diabetes                    32.1             25.6                    36.1                     40.1           \<0.0001
   Hypertension                73.5             65.5                    77.0                     87.4           \<0.0001
   Hyperlipidaemia             62.8             49.2                    73.0                     75.8           \<0.0001
   Smoking                                                                                                      0.0029
    Never/missing/unknown      50.2             54.2                    44.4                     53.6           
    Former/current smoker      49.8             45.8                    55.6                     46.4           
   Active endocarditis         1.5              3.2                     0.2                      0.0            \<0.0001
  Cardiac history                                                                                               
   History of MI†              12.7             5.0                     16.4                     25.6           \<0.0001
   Recent MI‡                  9.2              4.3                     17.0                     3.4            \<0.0001
   Previous PCI                10.3             3.6                     10.6                     28.5           \<0.0001
   Previous CABG               7.6              2.9                     3.9                      30.4           \<0.0001
   CHF                         24.7             19.5                    19.9                     51.7           \<0.0001
   LVEF                                                                                                         0.0058
    ≥35%                       86.2             85.5                    86.7                     87.0           
    \<34%                      7.9              6.3                     8.5                      10.6           
    Unknown                    6.0              8.2                     4.8                      2.4            
  *Procedural factors*                                                                                          
   AV repair                   NA               1.0                     1.2                      NA             \<0.0001
   Other procedures§           NA               6.7                     6.6                      NA             0.0007
   Transfemoral approach       NA               NA                      NA                       76.8           \<0.0001
   Wait location                                                                                                \<0.0001
    Outpatient                 77.6             81.2                    67.4                     93.2           
    Inpatient¶                 22.4             18.8                    32.6                     6.8            
   Inpatient wait length                                                                                        \<0.0001
    ≤4 days                    81.5             85.0                    72.4                     94.2           
    ≥5 days                    18.5             15                      27.6                     5.8            
   Short length of stay\*\*    1.0              0.5                     0.8                      2.9            0.0097
   Long ICU length of stay††   25.8             16.1                    28.6                     46.4           \<0.0001

Unless otherwise specified, values represent proportions.

\*BMI: underweight=\<18.5, normal=18.5--24.9, overweight=25--29.9, obese=≥30.

†History of MI: MI \>30 days ago.

‡Recent MI: MI within the past 30 days.

§Other procedures: aneurysectomy, myectomy, atrial septal defect closure, ventricular septal defect closure, aortic surgery pericardectomy, arrhythmia surgery, cardiac tumour surgery, other surgery.

¶Wait location---inpatient=if wait location at referral, acceptance or booking is a hospital.

\*\*Short length of Stay: ≤2 days

††Long ICU length of Stay: ≥4 days.

AV, aortic valve; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; ICU, intensive care unit; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.

Procedures {#s3b}
----------

Less than 10% of the patients undergoing TAVI were urgent, and instead the major were outpatients who had elective procedures. There was a significantly higher proportion of urgent traditional SAVR cases. In addition, almost 47% of TAVI cases had long intensive care unit (ICU) stays of \>4 days, compared with 16.1% and 28.6% of the isolated SAVR and combination SAVR+CABG cases, respectively.

Cost of the index hospitalisation {#s3c}
---------------------------------

As expected, in-hospital costs for the episode of care were highly skewed with few outliers with very high costs ([figure 1](#OPENHRT2016000468F1){ref-type="fig"}). The mean and median costs for the isolated SAVR hospitalisation were \$29 163 and \$21 811, respectively, while for combination SAVR+CABG, the mean and median costs were \$36 131 and \$27 256. The costs for the index TAVI hospitalisation were higher with a mean cost of \$49 796 and median cost of \$42 742. In addition, the range in TAVI costs was greater with a wider IQR (\$37 295--\$56 196), compared with either SAVR (\$18 148--\$30 498) or SAVR+CABG (\$21 741--\$39 000).

![Box plots of costs for the index hospitalisation. The upper and lower margins of the boxes represent the first and third quartiles of cost. The middle line represents the median. For all procedures, the upper limit has been truncated and represented by the figure in the text box.](openhrt2016000468f01){#OPENHRT2016000468F1}

Drivers of costs {#s3d}
----------------

Several patient-level factors were associated with an increased cost for the index hospitalisation ([table 2](#OPENHRT2016000468TB2){ref-type="table"}). Age over 75 years was a significant predictor for increased costs for isolated SAVR and TAVI. For SAVR, renal dysfunction and in particular being on dialysis was an important driver of higher costs associated with a 35% increase in mean costs, as was active endocarditis (31% increase in costs). For TAVI, lung disease was the comorbidity with the greatest impact on costs with an RR of 1.26 (95% CI 1.12 to 1.40; p\<0.001), while active heart failure was a strong driver for combination CABG+SAVR (RR 1.28; 95% CI 1.16 to 1.41; p\<0.001).

###### 

Factors associated with total cost in SAVR, SAVR with CABG and TAVI

                               Isolated SAVR             SAVR with CABG   TAVI                                                               
  ---------------------------- ------------------------- ---------------- ------------------------- -------------- ------------------------- --------------
  *Patient-level factors*                                                                                                                    
  Demographics                                                                                                                               
   Age                                                                                                                                       
    20--74                     Referent                                                                                                      
    75+                        **1.12 (1.05 to 1.19)**   **0.0007**       1.04 (0.97 to 1.12)       0.3015         **1.13 (1.01 to 1.26)**   **0.0295**
   Male                        Referent                                                                                                      
   Female                      1.01 (0.95 to 1.07)       0.7772           1.04 (0.96 to 1.13)       0.3139         1.06 (0.97 to 1.16)       0.2298
  Medical comorbidities                                                                                                                      
   COPD                        1.13 (1.00 to 1.28)       0.0515           1.10 (0.97 to 1.24)       0.1332         **1.26 (1.12 to 1.40)**   **0.0001**
   CVD                         **1.21 (1.09 to 1.35)**   **0.0006**       1.01 (0.90 to 1.13)       0.8652         1.04 (0.94 to 1.15)       0.4138
   PVD                         1.04 (0.91 to 1.18)       0.5960           1.05 (0.96 to 1.16)       0.2876         0.97 (0.88 to 1.07)       0.5304
   BMI\*                                                                                                                                     
    Underweight/normal         Referent                                                                                                      
    Overweight                 1.00 (0.93 to 1.07)       0.9645           1.07 (0.97 to 1.17)       0.1604         0.93 (0.85 to 1.02)       0.1291
    Missing                    0.99 (0.87 to 1.13)       0.9130           1.06 (0.88 to 1.28)       0.5572         0.95 (0.79 to 1.14)       0.5678
   Renal function                                                                                                                            
    Creatinine 0--140 μmol/L   Referent                                                                                                      
    Creatinine \>140 μmol/L    **1.13 (1.01 to 1.26)**   **0.0371**       1.08 (0.94 to 1.23)       0.2616         1.00 (0.90 to 1.12)       0.9813
    Missing                    0.99 (0.88 to 1.11)       0.8393           0.92 (0.76 to 1.12)       0.4126         1.05 (0.91 to 1.21)       0.5361
   Dialysis                    **1.35 (1.02 to 1.78)**   **0.0347**       0.90 (0.72 to 1.13)       0.3565         1.19 (0.86 to 1.66)       0.2855
   Anticoagulant use           1.01 (0.92 to 1.11)       0.8365           1.00 (0.90 to 1.12)       0.9422         1.01 (0.92 to 1.10)       0.8295
  Cardiac risk factors                                                                                                                       
   Diabetes                    **1.09 (1.02 to 1.17)**   **0.0157**       0.98 (0.91 to 1.06)       0.6466         1.01 (0.93 to 1.10)       0.7275
   Hypertension                1.00 (0.94 to 1.07)       0.9826           1.04 (0.95 to 1.13)       0.4144         1.03 (0.92 to 1.17)       0.5974
   Hyperlipidaemia             1.00 (0.94 to 1.07)       0.9042           1.05 (0.96 to 1.14)       0.2696         0.96 (0.87 to 1.06)       0.3841
   Smoking                                                                                                                                   
    Never/missing/unknown      Referent                                                                                                      
    Former/current smoker      0.95 (0.89 to 1.01)       0.0733           0.97 (0.90 to 1.04)       0.3670         1.00 (0.92 to 1.09)       0.9593
   Active endocarditis         **1.31 (1.09 to 1.56)**   **0.0033**       1.09 (0.49 to 2.40)       0.8332         NA                        
  Cardiac history                                                                                                                            
   History of MI†              1.08 (0.93 to 1.24)       0.3303           1.06 (0.95 to 1.17)       0.2962         1.02 (0.93 to 1.13)       0.6109
   Recent MI‡                  **0.81 (0.69 to 0.94)**   **0.0054**       **1.16 (1.03 to 1.30)**   **0.0126**     1.24 (0.99 to 1.56)       0.0633
   Previous PCI                0.93 (0.79 to 1.10)       0.4010           1.09 (0.97 to 1.23)       0.1634         1.00 (0.91 to 1.09)       0.9574
   Previous CABG               1.03 (0.87 to 1.22)       0.7336           0.95 (0.79 to 1.14)       0.5784         1.09 (0.99 to 1.20)       0.0938
   CHF                         1.05 (0.97 to 1.14)       0.1971           **1.28 (1.16 to 1.41)**   **\<0.0001**   0.97 (0.88 to 1.06)       0.4490
   LVEF                                                                                                                                      
    ≥35%                       Referent                                                                                                      
    \<34%                      1.03 (0.90 to 1.16)       0.6973           0.95 (0.83 to 1.08)       0.4247         1.07 (0.93 to 1.23)       0.3282
    Unknown                    **0.89 (0.79 to 0.99)**   **0.0374**       1.04 (0.88 to 1.23)       0.6591         0.98 (0.76 to 1.26)       0.8787
  *Procedural factors*                                                                                                                       
   AV repair                   1.26 (0.94 to 1.69)       0.1179           0.90 (0.65 to 1.24)       0.5074         NA                        
   Other procedures§           **1.14 (1.02 to 1.28)**   **0.0260**       1.09 (0.96 to 1.25)       0.239          NA                        
  Transfemoral approach                                                                                                                      
   Yes                         **Referent**                                                                                                  
   No                          **NA**                                     **NA**                                   **1.31 (1.18 to 1.45)**   **\<0.0001**
   Wait location                                                                                                                             
    Outpatient                 Referent                                                                                                      
    Inpatient¶                 **1.41 (1.20 to 1.66)**   **\<0.0001**     1.02 (0.87 to 1.21)       0.7914         0.87 (0.60 to 1.27)       0.4768
   IP wait length                                                                                                                            
    IP ≤4 days                 Referent                                                                                                      
    IP ≥5 days                 0.94 (0.79 to 1.12)       0.4842           1.02 (0.87 to 1.21)       0.7768         1.44 (0.95 to 2.17)       0.0814
  Short length of stay\*\*                                                                                                                   
   Yes                         Referent                                                                                                      
   No                          1.28 (0.86 to 1.92)       0.2276           1.29 (0.87 to 1.92)       0.2068         **1.42 (1.14 to 1.78)**   **0.0023**
  Long ICU length of stay††                                                                                                                  
   No                          **Referent**                                                                                                  
   Yes                         **2.16 (1.99 to 2.35)**   **\<0.0001**     **2.05 (1.89 to 2.21)**   **\<0.0001**   **1.30 (1.20 to 1.41)**   **\<0.0001**

Bold values are statistically significant.

\*BMI: underweight=\<18.5, normal=18.5--24.9, overweight=25--29.9, obese=≥30.

†History of MI: MI \>30 days ago.

‡Recent MI: MI within the past 30 days.

§Other procedures: aneurysectomy, myectomy, atrial septal defect closure, ventricular septal defect closure, aortic surgery pericardectomy, arrhythmia surgery, cardiac tumour surgery, other surgery.

¶Wait location---inpatient=if wait location at referral, acceptance or booking is a hospital or EMS Direct.

\*\*Short length of stay: ≤2 days.

††Long ICU length of Stay: ≥4 days.

AV, aortic valve; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; ICU, intensive care unit; IP, inpatient; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; RR, rate ratio; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.

Procedural factors of importance included the wait-time location and urgency ([table 2](#OPENHRT2016000468TB2){ref-type="table"}). For TAVI, a non-transfemoral access was associated with an almost 30% increase in total costs. Patients undergoing TAVI who were discharged within 2 days of their procedure had a substantially lower cost compared with those with longer admissions (RR 1.42; 95% CI 1.14 to 1.78; p=0.0023). For all procedures, a long intensive care stay of \>3 days was a strong driver of increased costs.

Discussion {#s4}
==========

In this multicentre cohort study, we found wide variation in the cumulative healthcare costs associated with the index hospitalisation between SAVR, SAVR+CABG and TAVI and identified a number of potentially modifiable procedural drivers of healthcare costs. These represent areas for further study to determine if quality improvement initiatives targeting these areas will improve the efficiency of care delivery and translate to lower overall costs.

Although we found that the median costs for SAVR were substantially less than those for TAVI, it is important to recognise that the patients undergoing each of the procedures were vastly different, as is consistent with the high-risk/inoperable indication for TAVI. Multiple cost-effectiveness analyses have evaluated TAVI and SAVR for either inoperable or high-risk patients.[@R13] [@R28] These have generally found that TAVI is cost-effective. That said, even in these populations, previous literature has generally found TAVI to have higher overall costs.[@R13] This issue, coupled with a limited funding envelope and restricted capacity, reinforces the need to understand the major cost drivers. The transcatheter heart valve (THV) prosthesis itself has a substantial acquisition cost that is 5--6 times that of a surgical prosthesis. The bulk of the previous work on TAVI[@R17] [@R18] [@R20] [@R33] and SAVR[@R34] related costs has focused on the importance of complications and the incremental costs associated with them.

Our study contributes a number of novel insights to this body of literature. First, we found that the procedures had substantially different drivers of overall cost. There were a number of important patient-related factors that drove SAVR cost, including age, renal disease, lung disease, diabetes, recent myocardial infarction and endocarditis. In contrast, for TAVI, only older age and lung disease were statistically significant patient-level drivers. We hypothesise that the greater relative importance of patient factors for SAVR-related costs is because patients undergoing SAVR more likely represent the full spectrum of operative risk from low, intermediate and high risk. In contrast, those for TAVI are almost exclusively either at high or prohibitive risk. The fact that there is a greater spectrum of patients would translate to a potentially greater impact of patient selection on SAVR cost. Lung disease is increasingly recognised as a poor prognostic factor for patients undergoing TAVI---our finding that it is one of the few patient factors that influence TAVI-related costs is consistent with these previous findings.

Second, we found that procedural factors were key cost drivers in SAVR and TAVI. This is particularly important as these are modifiable. Both in TAVI and SAVR, the majority of the costs associated with the index episode of care are not prosthesis related. This is especially relevant to TAVI, given the high cost of THV currently. Although the acquisition cost of the THV prosthesis will decrease as technology improves and more transcatheter systems enter the marketplace, this is likely to be a protracted process. In contrast, the non-prosthesis-associated costs, in particular the potentially modifiable procedural drivers, are ones that may be more readily addressed in the short term. Indeed, there are a number of ongoing initiatives that are already targeting some of these drivers. Specifically, in TAVI, there is an emphasis on a 'minimalist' approach that uses local anaesthesia/conscious sedation rather than general anaesthesia.[@R35] [@R36] The goal is that a less invasive procedure, coupled with explicit clinical care pathways that aim to mobilise patients early, result in shorter ICU stays and earlier discharge, both of which were major drivers of lower costs. Our finding that non-transfemoral approaches were associated with higher resource use reinforces this point.

Our study must be interpreted in the context of several limitations that merit discussion. First, our healthcare cost estimates were from fiscal year 2012--2013. For TAVI, where there have been rapid technological and procedural refinements, these costs may not be representative of current costs. However, we would expect that many of the patient and procedural drivers highlighted are likely to continue to be important. Second, we focused solely on the costs associated with the index hospitalisation and these represent only a fraction of the overall healthcare costs associated with each of these procedures. Both SAVR and TAVI require an extensive preprocedural workup including evaluation by a multidisciplinary Heart Team and the need for multiple diagnostic modalities, including coronary angiography and CT imaging often. For TAVI, excluded costs would also include any preprocedural revascularisation by angioplasty, which would typically occur at a separate sitting. Finally, ours was an observational data set, and thus there was most likely residual confounding that we could not account for despite the use of advanced statistical techniques. As such, our findings should be considered hypothesis generating.

In conclusion, we identified a number of patient and procedural factors that impact on healthcare costs for the index hospitalisation; some of these are potentially modifiable and may represent areas for quality improvement to optimise healthcare delivery.
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